BLIS M18™ Probiotic Achieves US FDA GRAS "No Objection" Status

CARTHAGE, Mo. - May 9, 2019 - PRLog -- Blis Technologies Limited and Stratum Nutrition^®, the exclusive North American distributor for the Blis Technologies' ingredients, announce that their 2nd probiotic strain BLIS M18™, has received issuance of a U.S. Food and Drug Administration 'Letter of No Objection'. This follows the BLIS K12™ 'Letter of No Objection' in 2016.

Through the GRAS program, companies may submit their determination supported by research and expert review that a specific ingredient is Generally Recognized As Safe. The Letter of No Objection means that the FDA has reviewed the data and has no questions or objections regarding the submitted BLIS M18™ GRAS notice.  This milestone is further recognition of the robust safety data supporting the BLIS oral-cavity probiotics.

GRAS status adds a new level of credibility for BLIS M18™ and has the potential to open up opportunities with larger consumer food and beverage companies in the U.S., but also is recognized as a relevant and credible safety assessment by other countries and multinational companies.

"This is great news and confirmation on an incredible ingredient.  BLIS M18™ is the type of ingredient that should be on the Continuing Education Unit agenda for every Dentist and Dental Hygienist practicing today.  It's that good."

For more information about Stratum Nutrition and its branded ingredients, please visit our website, https://www.stratumnutrition.com/blogs/ingredient-news/blis-m18%E2%84%A2-probiotic-achieves-us-fda-gras-%E2%80%9Cno-objection%E2%80%9D-status .